Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

complementary therapies

- PMLiVE

Epilepsy takes centre stage in UK

National Epilepsy Week aims to raise awareness of the neurological condition

- PMLiVE

UCB names Jean-Christophe Tellier as Doliveux’s successor

He will take over take over leadership at the Belgium pharma company next year

- PMLiVE

UCB to sell Biogen Idec’s MS drugs in Asia

Includes Tysabri and Tecfidera

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Research Partnership

- PMLiVE

Matthew Speers appointed as new chief executive of PAGB

UCB's former UK and Ireland general manager will take up post next year

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Research Partnership

Sanofi reception

Sanofi moves closer to arthritis drug filing

Reports positive late-stage results for sarilumab

- PMLiVE

UCB files Vimpat for expanded epilepsy use

Submits monotherapy application to FDA


Bristol-Myers Squibb (BMS) building

Positive data for BMS’ clazakizumab in arthritis

Phase II results indicate drug is as effective as AbbVie’s Humira

- PMLiVE

UCB wins extra Cimzia approval in US

FDA backs drug for use in patients with active psoriatic arthritis 

- PMLiVE

Rigel plans job cuts in R&D restructure

Follows failure of fostamatinib disodium in rheumatoid arthritis trial

- PMLiVE

VIDEO interview: Neil Weir, UCB

Senior vice president of global research at UCB discusses the importance of patient-centricity and the value of collaboration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links